Research programme: musculoskeletal disorders - Apexis Bio
Latest Information Update: 19 Sep 2024
At a glance
- Originator Sirana Pharma
- Developer Apexis Bio; Pfizer
- Class MicroRNAs
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Musculoskeletal disorders